Clinical Trials Browser

Phase 2/3 × Enrolling by invitation × Cisplatin × Clear all

NCT06755515 2025-01-01

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Phase 2/3 Enrolling by invitation

Uterine Cervical Neoplasms